Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC. Weigelt B, et al. Among authors: meisel jl. Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1. Clin Cancer Res. 2017. PMID: 28765325 Free PMC article.
Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management.
Liu YL, Manning-Geist BL, Knezevic A, Deng L, Bromberg M, Funt SA, Meisel JL, Zivanovic O, Roche KL, Sonoda Y, Gardner GJ, Grisham RN, O'Cearbhaill RE, Tew WP, Abu-Rustum NR, Chi DS, Aghajanian C, Feldman DR. Liu YL, et al. Among authors: meisel jl. Gynecol Oncol. 2023 Mar;170:93-101. doi: 10.1016/j.ygyno.2022.12.022. Epub 2023 Jan 18. Gynecol Oncol. 2023. PMID: 36669327 Free PMC article.
Wilms' tumor of the ovary.
Alexander VM, Meisel J, O'Brien S, Khanna N. Alexander VM, et al. Gynecol Oncol Rep. 2016 Dec 14;19:18-21. doi: 10.1016/j.gore.2016.12.004. eCollection 2017 Feb. Gynecol Oncol Rep. 2016. PMID: 28018955 Free PMC article.
A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).
Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC. Patel TA, et al. Among authors: meisel jl. Breast Cancer Res. 2019 Sep 2;21(1):100. doi: 10.1186/s13058-019-1186-0. Breast Cancer Res. 2019. PMID: 31477168 Free PMC article. Clinical Trial.
Optimizing the Duration of Trastuzumab: A Fresh Perspective.
Taylor MA, Byers KF, Meisel JL. Taylor MA, et al. Among authors: meisel jl. Oncology (Williston Park). 2020 Aug 12;34(8):296-301. doi: 10.46883/ONC.2020.3408.0296. Oncology (Williston Park). 2020. PMID: 32785922
66 results